<DOC>
	<DOC>NCT02569801</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of GDC-0810 compared with fulvestrant in postmenopausal women with advanced or metastatic estrogen receptor positive (ER+)/ human epidermal growth factor receptor 2 negative (HER2) breast cancer resistant to aromatase inhibitor therapy.</brief_summary>
	<brief_title>A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy (HydranGea)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Postmenopausal women with histologically or cytologically confirmed metastatic or inoperable, locally advance breast cancer Participants for whom endocrine therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or nonmeasurable, evaluable disease with atleast one evaluable bone lesion by RECIST v1.1 Participants must have radiologic/objective evidence of breast cancer recurrence or progression while on or within 6 months after the end of adjuvant treatment with an Aromatase Inhibitor (AI), or progression while on or within 1 month after the end of prior AI treatment for locally advanced or Metastatic Breast Cancer Participants must have Estrogen Receptor Positive (ER+) disease HER2 positive disease Prior treatment with fulvestrant Prior treatment with greater than (&gt;)1 cytotoxic chemotherapy regimen Prior treatment with &gt; 2 endocrine therapies</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>